Chardan lowered the firm’s price target on Intellia Therapeutics to $107 from $111 and keeps a Buy rating on the shares after the company presented updated interim data on in vivo liver-directed editing program NTLA-2002 for hereditary angioedema, or HAE, at the European Academy of Allergy and Clinical Immunology, or EAACI, congress. The firm increased its view on the program’s odds of success to 65% from 55% on the durable knockdown and attack rate reductions, but conservatively slow its ramp for one-time genetic medicines to a cumulative 15% of the eligible HAE population by 2030 from a prior forecast of 20%, driving its change in price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NTLA:
- Intellia Rises on Promising Phase 1 Data in Hereditary Angioedema
- Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
- Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
- Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities